SUPPLEMENTARY TABLE. Early Estimates of Updated 2023–2024 (monovalent XBB.1.5) COVID-19 Vaccine Effectiveness Against Symptomatic SARS-CoV-2 Infection Attributable to Co-circulating Omicron Variants Among Immunocompetent Adults — Increasing Community Access to Testing Program, United States, September 2023 – January 2024
Advanced Search
Select up to three search categories and corresponding keywords using the fields to the right. Refer to the Help section for more detailed instructions.

Search our Collections & Repository

For very narrow results

When looking for a specific result

Best used for discovery & interchangable words

Recommended to be used in conjunction with other fields

Dates

to

Document Data
Library
People
Clear All
Clear All

For additional assistance using the Custom Query please check out our Help Page

i

SUPPLEMENTARY TABLE. Early Estimates of Updated 2023–2024 (monovalent XBB.1.5) COVID-19 Vaccine Effectiveness Against Symptomatic SARS-CoV-2 Infection Attributable to Co-circulating Omicron Variants Among Immunocompetent Adults — Increasing Community Access to Testing Program, United States, September 2023 – January 2024

Filetype[PDF-138.40 KB]


English
Details Related Documents You May Also Like

Details:

Supporting Files

  • No Additional Files
More +

Related Documents

You May Also Like

Checkout today's featured content at stacks.cdc.gov